Pharmacokinetic/pharmacodynamic feedback modelling of the functional corticosterone response in rats after acute treatment with escitalopram

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 3, 2007, Pages 182-189

  Bundgaard, Christoffer ^a   Larsen, Frank ^a   Jørgensen, Martin ^a   Mørk, Arne ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; AUTOANALYSIS; BLOOD SAMPLING; CONSCIOUSNESS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG RESPONSE; EXPERIMENTAL MODEL; FEEDBACK SYSTEM; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CITALOPRAM; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDBACK, BIOCHEMICAL; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

RATTUS;

EID: 33847041445     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.00029.x     Document Type: Article

References (31)

1. Sánchez C, Bergqvist PB, Brennum LT et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003;167:353-62.
2. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A doubleblind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21:159-69.
3. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006;7:429-40.
4. Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999;51:533-91.
5. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 2000;14:177-85.
6. Jensen JB, Jessop DS, Harbuz MS, Mørk A, Sánchez C, Mikkelsen JD. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 1999;11:465-71.
7. Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 1999;65:1217-35.
8. Dinan TG. Serotonin and the regulation of hypothalamicpituitary-adrenal axis function. Life Sci 1996;58:1683-94.
9. Fuller RW, Perry KW, Hemrick-Luecke SK, Engleman E. Serum corticosterone increases reflect enhanced uptake inhibitorinduced elevation of extracellular 5-hydroxytryptamine in rat hypothalamus. J Pharm Pharmacol 1996;48:68-70.
10. Holsboer F, Barden N. Antidepressants and hypothalamicpituitary- adrenocortical regulation. Endocr Rev 1996;17:187-205.
11. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
12. Bundgaard C, Larsen F, Jørgensen M, Gabrielsson J. Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. Eur J Pharm Sci 2006;29:394-404.
13. Van Dongen JJ, Remie R, Rensema JW, van Wunnik GHJ. Manual of Microsurgery on the Laboratory Rat. Elsevier Science Publishers BV, Maastricht, The Netherlands, 1990.
14. Diehl KH, Hull R, Morton D et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001;21:15-23.
15. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 1997;9:686-92.
16. Woodward CJ, Emery PW. Determination of plasma corticosterone using high-performance liquid chromatography. J Chromatogr 1987;419:280-4.
17. Wong YN, Chien BM, D'mello AP. Analysis of corticosterone in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994;661:211-8.
18. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78.
19. Mørk A, Kreilgaard M, Sánchez C, Brennum L, Wiborg O. In vitro and in vivo effects of citalopram and its enantiomers on the serotonin uptake transporter. Eur Neuropsychopharmacol 2002;12 (Suppl 3):S224.
20. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004;77:391-8.
21. Jusko WJ. Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Toxicology 1995;102:189-96.
22. Gabrielsson J, Jusko WJ, Alari L. Modelling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos 2000;21:41-52.
23. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003;43:1216-27.
24. Yao Z, DuBois DC, Almon RR, Jusko WJ. Modelling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res 2006;23:670-9.
25. Zuideveld KP, van Gestel A, Peletier LA, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol 2002;445:43-54.
26. Sainio EL, Lehtola T, Roininen P. Radioimmunoassay of total and free corticosterone in rat plasma: measurement of the effect of different doses of corticosterone. Steroids 1988;51:609-22.
27. Windle RJ, Wood SA, Shanks N, Lightman SL, Ingram CD. Ultradian rhythm of basal corticosterone release in the female rat: dynamic interaction with the response to acute stress. Endocrinology 1998;139:443-50.
28. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. Pharmacokinetic- pharmacodynamic modelling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 1998;284:1095-103.
29. Derendorf H, Lesko LJ, Chaikin P et al. Pharmacokinetic/ pharmacodynamic modelling in drug research and development. J Clin Pharmacol 2000;40:1399-418.
30. Søgaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005;45:1400-6.
31. Jongsma ME, Bosker FJ, Cremers TI, Westerink BH, den Boer JA. The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin1B receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:738-44.